Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis

被引：0

作者：

Brunner, Christine

Jaeger, Thomas

Suppan, Christoph

Mueller-Holzner, Elisabeth

Jasarevic, Zerina

Balic, Marija

Goebel, Georg

Marth, Christian

Stoeger, Herbert

Samonigg, Hellmut

Hubalek, Michael

Lang, Alois

机构：

[1] Dept Gynecol & Obstet, Innsbruck, Austria

[2] LKH Feldkirch, Feldkirch, Austria

[3] Med Univ Graz, Dept Internal Med, Graz, Austria

[4] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria

[5] Breast Canc Ctr Vorarlberg, Feldkirch, Austria

[6] Med Univ Graz, Graz, Austria

[7] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Oecon, A-6020 Innsbruck, Austria

[8] Med Univ Graz, Dept Med Oncol, Graz, Austria

[9] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria

[10] Acad Teaching Hosp, Feldkirch, Austria

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

583

引用

页数：1

共 50 条

[41] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
Burstein, HJ
Kuter, I
Campos, SM
Gelman, RS
Tribou, L
Parker, LM
Manola, J
Younger, J
Matulonis, U
Bunnell, CA
Partridge, AH
Richardson, PG
Clarke, K
Shulman, LN
Winer, EP
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2722 - 2730
[42] Multicenter phase I/II study of efficacy, safety, and pharmacokinetics of vinorelbine and trastuzumab as first-line therapy for HER2-overexpressing metastatic breast cancer
Aogi, Kenjiro
Toi, Masakazu
Iwata, Hiroji
Ito, Yoshinori
Sano, Muneaki
Sato, Yasuyuki
Saeki, Toshiaki
Takashima, Shigemitsu
ANNALS OF ONCOLOGY, 2006, 17 : 75 - 76
[43] Role of HSP27 in trastuzumab resistance in HER2-overexpressing breast cancer
Hwang, S-Y.
Choi, S-K.
Na, Y.
Lee, Y-S.
Kwon, Y.
ANNALS OF ONCOLOGY, 2017, 28 : 24 - 24
[44] Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
Mann, K.
Kullberg, M.
CANCER GENE THERAPY, 2016, 23 (07) : 221 - 228
[45] Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial
Chia, Stephen
Clemons, Mark
Martin, Lee-Ann
Rodgers, Angela
Gelmon, Karen
Pond, Gregory R.
Panasci, Lawrence
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2773 - 2778
[46] Efficacy and prognosis of adjuvant trastuzumab therapy in Ti HER2-overexpressing early primary breast cancer: A single-center restrospective analysis.
Gang, Sun
Le, Yang
Zhou, Li Fan
Bin, Ma
Bin Lin, Ma
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[47] A randomized, opened, phase II trial assessing the efficacy and safety of ATH-TH(doxorubicin/docetaxel/trastuzumab followed by docetaxel/trastuzumab) versus TCH(docetaxel/carboplatin/trastuzumab) as neoadjuvant treatment in HER2-positive breast cancer
Wang, Tao
Zhou, Jin-Mei
Hao, Xiao-Peng
Zhang, Hui-Qaing
Zhang, Shao-Hua
Bian, Li
Jiang, Ze-Fei
CANCER RESEARCH, 2021, 81 (04)
[48] Neoadjuvant dose-dense docetaxel, carboplatinum, and trastuzumab (ddTCH) chemotherapy for HER2 overexpressing breast cancer
Bayraktar, S.
Bayraktar, U. D.
Reis, I. M.
Pegram, M.
Welsh, C.
Silva, O.
Franchesci, D.
Gomez, C. R.
Hurley, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[49] Liposomal doxorubicin in combination with trastuzumab and docetaxel as first line chemotherapy in HER-2 metastatic breast cancer patients
Bighin, C.
Puglisi, F.
Cavazzini, G.
Olmeo, N.
Colucci, G.
Garrone, O.
Paccagnella, A.
Labianca, R.
Crino, L.
Simoncini, E.
Manzione, L.
Nardi, M.
Cortesi, E.
Venturini, M.
ANNALS OF ONCOLOGY, 2005, 16 : 9 - 9
[50] Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer
Shen, Yuanyuan
Hua, Qingling
Dong, Menghao
Jin, Wei
Hu, Xueyang
Gu, Kangsheng
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12

← 1 2 3 4 5 →